MGI Tech Co., Ltd. and JCBio Co., Ltd. have signed a Memorandum of Understanding to launch the DCS Lab Project, marking a significant milestone in South Korea's genomics landscape. The collaboration aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights by combining MGI's advanced omics technologies with JCBio's established local expertise.
Comprehensive Multi-Omics Platform Integration
The partnership equips JCBio's laboratories with MGI's proprietary short-read and long-read sequencing technologies, providing end-to-end multi-omics capabilities. This integration enables researchers to tackle complex biological challenges with enhanced precision and efficiency, positioning JCBio as a local hub for cutting-edge genomic research and multi-omics innovation.
Under the DCS Lab Project framework, JCBio will implement innovative sequencing strategies, advance integrated multi-omics analyses, and explore novel sequencing applications. The collaboration specifically focuses on accelerating precision medicine initiatives and clinical translation while leveraging AI-driven data insights to maximize research impact.
Expanding Global DCS Lab Initiative
MGI's DCS Lab Initiative, launched in 2023, represents the company's first global program targeting international laboratories with a focus on frontier science. Named after MGI's three core technologies—DNA genomics, Cell omics, and Spatial omics—the initiative demonstrates MGI's unique industry capability to provide comprehensive end-to-end products across diverse omics applications.
The program has already demonstrated success at MGI's Customer Experience Centre in Australia, where technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer research, medicine, and agriculture. The South Korea expansion with JCBio builds on this proven track record.
Strategic Leadership Perspectives
"We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation," said Dr. Roy Tan, Director of MGI Northeast Asia. "With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea's research community with the tools to drive frontier science and improve human health."
JaeChan Yoo, CEO of JCBio, emphasized the transformative potential of the collaboration: "This partnership with MGI is a game-changer for South Korea's research community. By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea's growing role in global genomics research."
Strengthening Regional Biotechnology Leadership
The collaboration reinforces South Korea's position as a key hub in Asia's rapidly growing biotech ecosystem. JCBio, founded in 2005, has established itself as a leading provider of research and diagnostic products in South Korea's life sciences sector, with a mission to enhance longevity and improve quality of life.
MGI Tech, founded in 2016, has grown into a global leader in life sciences, serving customers across six continents with research, manufacturing, training, and after-sales service facilities worldwide. The company stands out as one of the few organizations capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels.
